Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$133.00K$133.00Kderived+11.8% vs Q4 2020 Net Income-$9.44M-$9.44MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$9,526,000N/M Operating Cash Flowderived-$7,390,000N/M Free Cash Flowderived-$7,497,000N/M Margins · derivedOperating margin-7162.4%−1702.7 pt vs Q4 2020
Net margin-7099.2%−1555.6 pt vs Q4 2020
ended Dec 31, 2021 · filed Feb 24, 2022 · 55 d after period end